Market Alert: ASX200 at Critical Support – Reversal or Further Fall?
AnteoTech Ltd (ASX: ADO) has released its interim financial report for the half-year ended 31 December 2024, reporting a 74% increase in operating revenue to AU$660,000. Despite this growth, total revenue and other income declined 24% to AU$3.185 million, primarily due to a 34% drop in interest and other income. The net loss for the period narrowed 7% to AU$2.195 million. AnteoTech continued its commercialization initiatives, with strong momentum in both the clean energy and life sciences sectors.
Key developments include the first commercial revenues from Ultranode sales to Mercedes Benz, ongoing technology trials with battery manufacturers, and a five-year supply agreement with Serum Institute of India valued at AU$1.8 million. The company also expanded its sales funnel in Europe, the US, and India, advancing discussions with partners across the battery value chain and in vitro diagnostics sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 15, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
